Literature DB >> 7831442

Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.

M G Palfreyman1, C J Schmidt, S M Sorensen, M W Dudley, J H Kehne, P Moser, M W Gittos, A A Carr.   

Abstract

Several lines of evidence have suggested a link between serotonergic and dopaminergic systems in the brain. The interpretation of much of these early data needs careful reevaluation in light of the recent understanding of the plethora of serotonin receptor subtypes, their distribution in the brain and the new findings with more selective serotonin antagonists. Electrophysiological, biochemical and behavioral evidence obtained using highly selective antagonists of the 5-HT2 or 5-HT3 receptor subtypes, MDL 100,907 or MDL 73,147EF, respectively, supports the thesis that serotonin modulates the dopaminergic system. This modulation is most evident when the dopaminergic system has been activated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7831442     DOI: 10.1007/bf02245008

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.

Authors:  G J Kilpatrick; B J Jones; M B Tyers
Journal:  Nature       Date:  1987 Dec 24-31       Impact factor: 49.962

2.  Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites.

Authors:  C T Giambalvo; S R Snodgrass
Journal:  Brain Res       Date:  1978-09-08       Impact factor: 3.252

3.  L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.

Authors:  C J Schmidt; C K Black; V L Taylor
Journal:  Eur J Pharmacol       Date:  1991-10-02       Impact factor: 4.432

4.  Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors.

Authors:  P Greengrass; R Bremner
Journal:  Eur J Pharmacol       Date:  1979-05-01       Impact factor: 4.432

Review 5.  Biochemical indentification of the mammalian muscarinic cholinergic receptor.

Authors:  S H Snyder; K J Chang; M J Kuhar; H I Yamamura
Journal:  Fed Proc       Date:  1975-09

6.  5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa.

Authors:  C J Schmidt; V L Taylor; G M Abbate; T R Nieduzak
Journal:  J Pharmacol Exp Ther       Date:  1991-01       Impact factor: 4.030

7.  Strychnine binding associated with glycine receptors of the central nervous system.

Authors:  A B Young; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

8.  Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT.

Authors:  H Gozlan; S El Mestikawy; L Pichat; J Glowinski; M Hamon
Journal:  Nature       Date:  1983 Sep 8-14       Impact factor: 49.962

9.  Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine.

Authors:  C J Schmidt; C K Black; V L Taylor
Journal:  Eur J Pharmacol       Date:  1990-05-31       Impact factor: 4.432

Review 10.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

View more
  26 in total

1.  5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic study.

Authors:  Shu Hasegawa; Maraki Fikre-Merid; Mirko Diksic
Journal:  Brain Res Bull       Date:  2011-10-25       Impact factor: 4.077

2.  5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats.

Authors:  R A Padich; T C McCloskey; J H Kehne
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats.

Authors:  J H Kehne; R A Padich; T C McCloskey; V L Taylor; C J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 4.  The biochemistry of Tourette's syndrome.

Authors:  P R Chokka; G B Baker; R A Bornstein; C M de Groot
Journal:  Metab Brain Dis       Date:  1995-06       Impact factor: 3.584

Review 5.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

6.  The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.

Authors:  Svetlana Semenova; Athina Markou
Journal:  Eur Neuropsychopharmacol       Date:  2010-06-03       Impact factor: 4.600

Review 7.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Authors:  K D Alex; E A Pehek
Journal:  Pharmacol Ther       Date:  2006-10-17       Impact factor: 12.310

8.  Effects of 5-hydroxytryptamine 2C receptor agonist MK212 and 2A receptor antagonist MDL100907 on maternal behavior in postpartum female rats.

Authors:  Weihai Chen; Qi Zhang; Wenxin Su; Haorong Zhang; Yu Yang; Jing Qiao; Nan Sui; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2013-12-07       Impact factor: 3.533

9.  [3H]MDL 100,907: a novel selective 5-HT2A receptor ligand.

Authors:  M P Johnson; B W Siegel; A A Carr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

Review 10.  The role of different serotonin receptor subtypes in seizure susceptibility.

Authors:  Mohammad Hadi Gharedaghi; Mohammad Seyedabadi; Jean-Eric Ghia; Ahmad Reza Dehpour; Reza Rahimian
Journal:  Exp Brain Res       Date:  2013-11-14       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.